Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice

Tsuyoshi Itoh, Esteban Celis

Research output: Contribution to journalArticle

34 Scopus citations


Much attention has been focused on transcutaneous immunization strategies to stimulate systemic cytotoxic T lymphocyte responses leading to anti-tumor or anti-microbial immunity. Here we report that topical application of vaccines consisting of synthetic peptides formulated with imiquimod, a Toll-like receptor agonist that functions as a potent adjuvant generates strong T cell responses that exhibit effective anti-tumor effects in a murine melanoma model system. These results support the use of peptide-based transcutaneous vaccines as a noninvasive and effective strategy for anti-tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)430-437
Number of pages8
JournalJournal of Immunotherapy
Issue number5
Publication statusPublished - Jan 1 2005
Externally publishedYes



  • Animal model
  • Cutaneous vaccine
  • Melanoma
  • Toll-like receptor adjuvant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this